PharmassetX raised $0.15 million to advance galenexib, an FDA-designated orphan drug for the treatment of pouchitis, a rare chronic inflammatory disease.
PharmassetX raised $0.15 million to advance galenexib, an FDA-designated orphan drug for the treatment of pouchitis, a rare chronic inflammatory disease.